14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $3.81 $4.81 Thursday, 2nd May 2024 NVAX stock ended at $4.71. This is 0.86% more than the trading day before Wednesday, 1st May 2024. During the day the stock fluctuated 3.80% from a day low at $4.60 to a day high of $4.78.
90 days $3.53 $6.05
52 weeks $3.53 $11.36

Historical Novavax Inc prices

Date Open High Low Close Volume
Jan 16, 2024 $4.43 $4.48 $4.28 $4.34 6 955 506
Jan 12, 2024 $4.56 $4.73 $4.54 $4.58 6 254 909
Jan 11, 2024 $4.80 $4.81 $4.55 $4.56 7 829 181
Jan 10, 2024 $4.87 $4.92 $4.70 $4.84 5 078 247
Jan 09, 2024 $5.10 $5.10 $4.63 $4.81 15 422 976
Jan 08, 2024 $4.96 $5.19 $4.88 $5.15 8 924 704
Jan 05, 2024 $5.02 $5.11 $4.86 $5.00 7 572 935
Jan 04, 2024 $4.91 $5.20 $4.82 $5.16 9 632 340
Jan 03, 2024 $5.00 $5.00 $4.78 $4.89 10 315 206
Jan 02, 2024 $4.82 $5.34 $4.77 $5.03 13 487 431
Dec 29, 2023 $4.90 $5.02 $4.80 $4.80 7 088 964
Dec 28, 2023 $4.95 $5.02 $4.84 $4.91 6 787 690
Dec 27, 2023 $5.02 $5.08 $4.89 $4.94 7 727 407
Dec 26, 2023 $5.15 $5.19 $5.03 $5.05 4 681 700
Dec 22, 2023 $4.94 $5.17 $4.90 $5.06 7 878 477
Dec 21, 2023 $4.99 $5.11 $4.93 $4.94 7 048 142
Dec 20, 2023 $5.18 $5.19 $4.85 $4.91 12 622 540
Dec 19, 2023 $5.18 $5.32 $5.18 $5.23 5 693 017
Dec 18, 2023 $5.36 $5.39 $5.07 $5.16 11 187 626
Dec 15, 2023 $5.73 $5.83 $5.38 $5.40 19 875 259
Dec 14, 2023 $5.58 $5.88 $5.45 $5.69 14 738 585
Dec 13, 2023 $5.21 $5.42 $5.06 $5.36 9 229 907
Dec 12, 2023 $5.57 $5.57 $5.19 $5.31 8 104 919
Dec 11, 2023 $5.62 $5.77 $5.52 $5.57 6 899 695
Dec 08, 2023 $5.50 $5.62 $5.43 $5.57 4 987 262
Click to get the best stock tips daily for free!

About Novavax Inc

Novavax Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical tria... NVAX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT